Authors' recommendations: Ropinirole prolonged-release (Requip XL®) is recommended for use within NHS Wales for the treatment of idiopathic Parkinson's disease in patients already taking ropinirole immediate-release tablets (Requip®) and in whom adequate symptomatic control has been established. Substitution of ropinirole prolonged-release tablets for ropinirole immediate-release may be used as: (i) Monotherapy, alone (without levodopa) in idiopathic Parkinson's disease (ii) Adjunctive therapy in addition to levodopa to control 'on-off' fluctuations which might permit a reduction in the total daily dose of levodopa. In order to limit errors, prolonged-release ropinirole should be prescribed by brand as Requip XL®. AWMSG is of the opinion that prolonged-release ropinirole (Requip XL®) may be suitable for shared care in accordance with appropriate guidance.

Project Status: Completed

Year Published: 2009

URL for published report: http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=131386&pid=24773

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC